Replies to post #35056 on Biotech Values

[gofishmarko]

>>> Nope! c) is not the most important and there’s a good reason for that if you think about it. <<<

I figured that if biweekly dosing allowed Albuferon to capture a 50% market share with no better efficacy / tolerability , then less frequent dosing is a major driver in determining preference , since you would only expect an even split , all other things being equal , between Pegasys , PegIntron , and Albuferon , i.e. a 33% share for Albuferon.

If the competition is only Pegasys , then I would say b , a , c.